Korean J Med.  2019 Dec;94(6):485-494. 10.3904/kjm.2019.94.6.485.

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

Affiliations
  • 1Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
  • 2Department of Endocrinology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
  • 4Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
  • 5Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
  • 6Department of Endocrinology and Metabolism, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea.
  • 7Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 8Department of Endocrinology and Metabolism, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju, Korea.
  • 9Department of Endocrinology and Metabolism, Seoul National University Hospital, Seoul, Korea.
  • 10Division of Geriatrics, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • 11Department of Internal Medicine, Medical School of Chonbuk National University, Jeonju, Korea.
  • 12Department of Endocrinology and Metabolism, Ajou Medical Center, Ajou University School of Medicine, Suwon, Korea.
  • 13Department of Endocrinology, Dongguk University Gyeongju Hospital, Gyeongju, Korea.
  • 14Department of Endocrinology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea.
  • 15Department of Endocrinology and Metabolism, Inje University Busan Paik Hospital, Busan, Korea.
  • 16Division of Endocrinology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Korea.
  • 17Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea.
  • 18Department of Endocrinology and Metabolism, Hanyang University College of Medicine, Seoul, Korea. dongsun@hanyang.ac.kr
  • 19Department of Endocrinology and Metabolism, Sejong General Hospital, Bucheon, Korea. drangelkr@sejonggh.co.kr

Abstract

Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.

Keyword

Acromegaly; Somatostatin; Octreotide; Lanreotide; Pasireotide

MeSH Terms

Acromegaly*
Expert Testimony
Growth Hormone
Humans
Octreotide
Pituitary Neoplasms
Somatostatin*
Growth Hormone
Octreotide
Somatostatin
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr